Tuesday, September 22, 2026

Occurrence of #influenza #antivirals and #resistance development in #influenza A viruses in aquatic #environments: A risk assessment

 


Abstract

Influenza antivirals (IAs) have been detected in aquatic environments inhabited by dabbling ducks, the natural reservoir of influenza A virus (IAV), raising concerns about the development of antiviral resistance. Because novel human IAV strains often contain genetic material of avian origin, this may contribute to resistance in viruses with pandemic potential. This study aimed to assess the environmental risk posed by four IAs—oseltamivir carboxylate (OC), zanamivir (ZA), peramivir (PE), and amantadine (AM)—based on their potential for environmental release, environmental stability, and induction of antiviral resistance. The assessment combined data from new experiments on (1) environmental release and (2) environmental stability of PE, AM, OC, and ZA, with results from previously published in vivo experiments in a mallard model examining (3) resistance development to OC, PE, and ZA in IAV. The risk of environmental release was assessed as high for OC, AM, and PE, and very high for ZA. Environmental stability ranged from very high to low, in the order PE > AM > OC > ZA. The potential to induce resistance in IAV was similar for PE and OC, and lower for ZA. Overall, the environmental risk ranking was PE > OC > ZA, with PE and OC posing the highest risks. Prudent use of IAs requires balancing the risk of resistance development against clinical benefit. In cases of complicated influenza or in high-risk patient groups, the clinical benefits are substantial and justify IA use. However, in uncomplicated influenza among otherwise healthy individuals, the clinical benefit is limited, and the risk of resistance development should be carefully considered. Among the evaluated antivirals, ZA showed the lowest environmental risk and should be preferred when feasible.

Source: 


Link: https://doi.org/10.1371/journal.pone.0358447

____

#Oropouche virus disrupts #neurodevelopment and exhibits #congenital infection potential

 


Abstract

Oropouche virus (OROV) historically caused a self-limiting disease, yet recent strains have been clinically linked to congenital infection and neurodevelopmental disease. These observations highlight the need to study OROV as a congenital pathogen. Here, using both a historical and currently circulating strain, we show OROV infects neurons across differentiation states in human forebrain organoids. Compared with the neurotropic congenital pathogen Zika virus (ZIKV), OROV exhibits a heightened capacity for neuroinfection and pathology in both forebrain organoids and neonatal mice. The increased permissiveness of OROV is driven, in part, by a broader neuronal tropism and a relative insensitivity to neuronal type I interferon-mediated antiviral responses. Consistent with clinical observations, neonatal neuroinfection results in rapid and severe neuropathology marked by cerebral hemorrhage. Finally, using a transient type I interferon-blockade model, we demonstrate that OROV can productively infect the murine placenta and cause fetal growth restriction. Together, our complementary models support a unified framework in which placental and fetal barriers limit productive fetal brain infection, yet OROV exhibits marked neurotropism and neuropathogenic potential upon gaining access to developing neural tissues. These findings reinforce the need for vigilant monitoring of OROV as an emerging pathogen associated with adverse pregnancy outcomes and congenital disease.

Source: 


Link: https://doi.org/10.1038/s41467-026-77859-5

____

Molecular #Epidemiology and #Evolution of Swine #Influenza A Viruses, #Vietnam, 2020–2024

 


Abstract

Swine influenza A viruses (IAV-S) caused the 2009 H1N1 pandemic and pose a future zoonotic and pandemic threat. Vietnam represents a critical hotspot for IAV-S emergence within East and Southeast Asia, with dense swine and human populations and intensive livestock trade. We conducted genomic surveillance of IAV-S in Vietnam during 2020–2024, extending previous surveillance from 2013–2019. We identified multiple co-circulating H1 and H3 clades, including pandemic H1N1, Eurasian avian-like, and European lineages, by conducting phylogenetic analysis of 56 IAV-S isolates (21 H1N1, 31 H1N2, and 4 H3N2). Three H1 clades persisted exclusively in Vietnam, circulating up to 12 years. Phylogeographic analysis revealed multiple independent introduction events from North America, Europe, China, Thailand, and Cambodia. We detected extensive reassortment that frequently involved pandemic H1N1 virus internal genes. We identified several lineage-specific mutations associated with mammalian adaptation. Our findings underscore the ongoing IAV-S evolution and need for sustained surveillance in Vietnam.

Source: 


Link: https://doi.org/10.3201/eid3210.260593

____

Serological #Evidence of Widespread #Exposure to #H5 Avian #Influenza Virus in #Arctic #Foxes in #Svalbard, Norway

 


Abstract

The continued circulation of H5 clade 2.3.4.4b highly pathogenic avian influenza virus (HPAIV) has caused extensive mortality in wild bird populations worldwide with increasing spillover to mammals. In 2022, H5 HPAIV emerged in Svalbard, Norway, with subsequent detections in wild birds, walruses, polar bears, and arctic foxes. To understand the population-level exposure among Svalbard arctic foxes, we analysed body fluids from carcasses trapped in 2006-2015 (n = 56), 2023-2024 (n = 112), and 2024-2025 (n = 94) for antibodies to H5 avian influenza (anti-H5), influenza A nucleoprotein (anti-NP), and neuraminidase subtypes using ELISAs, haemagglutination inhibition (HI), and a multiplex assay. Only three samples from 2006-2015 tested positive for anti-H5 and were interpreted as false positives. In 2023-2024, seropositivity for anti-H5 was high (95%), supported by a lower anti-NP seropositivity (85%) and antibody profiles consistent with mixed H5N1 (42%) and H5N5 (52%) exposure. In 2024-2025, anti-H5 and anti-NP seroprevalences remained high (83% and 57%), with H5N5 (87%) exposure predominating over H5N1 (3%). A subset of anti-H5-positive samples tested positive by HI (2023-2024: 30%; 2024-2025: 14%). Juveniles with exposure limited to the previous season had higher odds of anti-H5 seropositivity in 2023-2024 than in 2024-2025 (OR 5.5). Analysis of paired lung extracts from a subset of individuals (n = 63) yielded results concordant with body fluids, using an indirect anti-H5 ELISA adapted for carnivores. Our findings demonstrate widespread H5 virus exposure. Together with occasional reports of progression to fatal HPAI, this highlights the need for continued population monitoring to evaluate ecological consequences.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

European Commission, https://ror.org/00k4n6c32, 101132473, 101084171

Dutch Research Council, ENWPP.SK.2025.001

Source: 


Link: https://doi.org/10.64898/2026.09.17.752278

____

#Taiwan, Seasonal #Influenza and #COVID19 Epidemics Weekly Report (CDC, Sept. 22 '26): #H1N1pdm09 & #SARS-CoV-2 PQ.16.1.1 viruses predominated

 


{Excerpt}

(...)

    The CDC noted that the influenza epidemic in Taiwan is slightly rising and in its epidemic season

    In week 37 (September 13-19), there were 141,375 outpatient and emergency room visits for influenza-like illnesses, a slight increase of 1.4% compared to the previous week. 

    Additionally, last week (September 15-21), there were 165 new cases of severe influenza complications (151 H1N1, 6 H3N2, and 8 untyped A cases) and 30 deaths (27 H1N1, 2 H3N2, and 1 untyped A case). 

    Laboratory monitoring data shows that the influenza virus currently circulating in the community is mainly type A, with type A H1N1 accounting for 84.9% of the cases. 

    This influenza season (2025-2026) saw a cumulative total of 1,586 severe cases (958 H1N1, 509 H3N2, 29 untyped type A, 90 type B) and 304 deaths (176 H1N1, 106 H3N2, 10 untyped type A, 12 type B). 

    Severe cases were predominantly among those aged 65 and above (65.8%) and those with a history of chronic diseases (83.2%). 67.8% of patients had not received the influenza vaccine this season.


    According to data from the Taiwan Centers for Disease Control (CDC), the COVID-19 epidemic in Taiwan is declining, but it is still in its epidemic period. 

    In the 37th week (September 13-19), there were 14,462 outpatient and emergency room visits related to COVID-19, a 20.6% decrease compared to the previous week (September 6-12). 

    Last week (September 15-21), there were 48 new severe cases and 9 new deaths

    Since October 2025, there have been a cumulative total of 723 cases of COVID-19 complicated by severe illness, of which 133 have died

    The majority of severe cases are among those aged 65 and above (73.3%) and those with a history of chronic diseases (82.6%). 83.8% of these cases have not received the COVID-19 vaccine this season. 

    In the past four weeks, the most prevalent local variants in cases have been NB.1.8.1 and PQ.16.1.1.

(...)

Source: 


Link: https://www.cdc.gov.tw/Bulletin/Detail/Tj9G4dJj3yMmEE0URl49CA?typeid=9

____

#Australia, #H5 avian #influenza events in #wildlife (DAFF, September 22 '26)



{Extracts}

(...)

Event data

    ° 621 Positive events

    ° 49,267 Hotline reports


    As of 4pm AEST, 21 September 2026, Australia has 621 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 318 in South Australia (SA)

        § 56 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 190 in Victoria (VIC)

        § 44 in Tasmania (TAS)

        § 1 in Other Territories*

{*} Jervis Bay Territory (Commonwealth jurisdiction)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.

(...)


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

Monday, September 21, 2026

Limited added #benefit of seasonal #influenza #vaccination before #H5 vaccination in mice and #ferrets challenged with #H5N1

 


ABSTRACT

Limited A(H5)-specific vaccine supply is expected early in a potential A(H5N1) pandemic, raising the question of whether licensed seasonal influenza vaccines could enhance protection when administered before A(H5) vaccination. We evaluated this strategy in mouse and ferret models using clade 2.3.4.4b A(H5N1) viruses. Seasonal influenza vaccination induced antibodies to seasonal haemagglutinins but did not induce detectable antibodies against A(H5) and did not consistently enhance A(H5)-directed antibody responses after A(H5) vaccination. In lethal challenge studies, seasonal vaccine priming before A(H5) vaccination was associated with improved outcomes compared with A(H5) vaccination alone in one of three mouse experiments, but this effect was not observed in the other two mouse experiments or in ferrets. These findings suggest that seasonal influenza vaccine priming provides limited added benefit to A(H5) vaccine-mediated protection against A(H5N1) under the conditions tested.

Source: 


Link: https://doi.org/10.1080/22221751.2026.2731495

____

Epidemiological #investigation of #Shuni virus #infections in #hospitals in two provinces of South Africa (2019–2021) using molecular and serological surveillance

 


Abstract

Shuni Virus (SHUV) is a reemerging zoonotic orthobunyavirus in the Peribunyaviridae family associated with neurological infections and birth defects in humans and animals in Africa and has emerged in the Middle East in the past 10 years. Limited epidemiological data exist in humans, partially due to a lack of clinical awareness and availability of diagnostic assays to determine the incidence of clinical cases and seroprevalence in the population. The goal of this study was to establish serologic and molecular diagnostic assays for SHUV for hospital-based surveillance and to investigate the clinical epidemiology in humans in South Africa. The incidence of SHUV infections was investigated in patients with acute fever of unknown cause with or without neurological signs (AFDUC/N) during the arbovirus season (January-June, 2019–2021). IgM and IgG ELISAs for SHUV were established using baculovirus-expressed glycoproteins and validated against virus-neutralization tests (VNT) positive sera. Orthobunyavirus quantitative RT-PCR (RT-qPCR) and IgM ELISA were used to identify acute infections, and IgG ELISA to define the seroprevalence in patients and healthy control groups in hospitals in Gauteng and Mpumalanga provinces in South Africa. In total, 3/349 (0.84%) AFDUC/N cases tested positive by RT-qPCR and confirmed as SHUV by sequencing. In total, 22/225 (9.7%) AFDUC/N patients had SHUV neutralising antibodies (VNT), of which 11/22 (50.00%) were IgM positive, with an IgM seropositivity of 4.89% (11/225 (4.89%)). Of the RT-PCR and double IgM + VNT+ patients, 60% presented with seizures and 40% with meningitis, of which 36.36% were children and 63.63% were adults, respectively. In total, 9/112 (8%) of the healthy control group tested positive on the IgG ELISA assay. These findings suggest that SHUV is a missed cause of acute neurological infections in hospitalized children and adults in South Africa and should be investigated in humans in Africa and other regions.

Source: 


Link: https://doi.org/10.1371/journal.pntd.0014738

____

#Global #framework to accelerate #action on avian #influenza (WOAH/FAO/WHO, September 21 '26, summary)

 


Required citationFAO, WHO, WOAH and CMS. 2026. Global framework to  accelerate action on avian influenza. Rome. https://doi.org/10.4060/ce1712en

The designations employed and the presentation of material in this information product do not imply the expression

of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO), the World

Health Organization (WHO), the World Organisation for Animal Health (WOAH) or the Convention on the Conservation of

Migratory Species of Wild Animals (CMS), concerning the legal or development status of any country, territory, city or area

or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or

products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or

recommended by FAO, WHO, WOAH or CMS in preference to others of a similar nature that are not mentioned.

The responsibility for the interpretation and use of the material lies with the reader, and in no event shall FAO, WHO,

WOAH or CMS be liable for damages arising from such interpretation or use.

ISBN 978-92-5-141028-8 [FAO]

ISBN (WHO) 978-92-4-012544-5 (electronic version)

ISBN (WHO) 978-92-4-012545-2 (print version)

© FAO, WHO and WOAH, 2026

Some rights reserved. This work is made available under the Creative Commons Attribution-NonCommercial-ShareAlike

3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo/ )

(...)

1. Introduction

Avian influenza is a complex global challenge with consequences for animal health,

human health, biodiversity, food security and livelihoods. In recent decades, high

pathogenicity avian influenza (HPAI) viruses have spread across continents, become

established in wild bird populations, affected an increasing range of mammalian species

and caused unprecedented impacts on wildlife, poultry production and associated

economies. These impacts are occurring alongside other environmental pressures

including climate change, habitat degradation and biodiversity loss.

Recognizing these challenges, the Food and Agriculture Organization of the United

Nations (FAO), the World Health Organization (WHO), the World Organisation for Animal

Health (WOAH) and the Convention on the Conservation of Migratory Species of Wild

Animals (CMS) have developed this global framework to strengthen collaboration on

avian influenza through a One Health approach.

This high-level framework is not intended to replace existing mandates, strategies or

technical guidance. Rather, it adds value by showing how existing mandates, strategies

and technical mechanisms can be better connected, aligned and communicated as part

of a shared One Health response to avian influenza. It reflects a recognition that no single

sector nor institution can address avian influenza alone, and that sustainable solutions

require coordinated efforts that integrate human, animal and environmental dimensions.

Developed through a participatory and consultative process, the framework draws

on the comparative strengths and roles of each organization (Figure 1). It emphasizes

the importance of human, domestic animal and wildlife surveillance, including in wild

birds, poultry and susceptible mammalian species, timely information and data sharing,

strong laboratory and workforce capacities, effective risk communication and sustained

investment in prevention and preparedness. It reinforces the principle that protecting

health is inseparable from protecting ecosystems and ensuring resilient agrifood systems.

Given the accelerating risks and impacts of avian influenza, there is an urgent need to

translate this framework into concrete action. This will require enhanced global support,

including increased and sustained investment in prevention, preparedness, surveillance,

mitigation and response capacities across sectors. The four organizations call on

governments, donors and partners to prioritize avian influenza within broader health

security and development agendas, and to mobilize the resources necessary to support

coordinated, country-led implementation of a One Health approach.

(...)

Source: 


Link: https://doi.org/10.4060/ce1712en

____

Sunday, September 20, 2026

Willow Mill, Albrecht Durer (1496 - 1498)

 


{Click on Image to Enlarge}

___

Public Domain.


Source: 


Link: https://www.wikiart.org/en/albrecht-durer/willow-mill-1498

____

Saturday, September 19, 2026

#Coronavirus Disease Research #References (AMEDEO, September 19 '26)

 


    Am J Obstet Gynecol

  1. HABBOUS S, Surani A, Leyland NA, Murji A, et al
    Uptake and outcomes associated with outpatient hysterectomy in Ontario, Canada.
    Am J Obstet Gynecol. 2026 Sep 18:S0002-9378(26)00500.
    PubMed         Abstract available


    Antiviral Res

  2. DU PONT V, Han D, Li J, Rodriguez L, et al
    Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions.
    Antiviral Res. 2026;255:106533.
    PubMed         Abstract available

  3. MARTINEZ-ARRIBAS B, Diaz-Gonzalez R, Weaver J, Walden M, et al
    Identification of 1,2-dihydroquinazolin-2-ones kinase inhibitors as anti-coronavirus agents.
    Antiviral Res. 2026 Sep 15:106534. doi: 10.1016/j.antiviral.2026.106534.
    PubMed         Abstract available

  4. NAGAHAWATTA DP, Jeong SH, Liyanage NM, Jayawardena TU, et al
    Marine phlorotannins block SARS-CoV-2 entry via ACE2 and attenuate pulmonary inflammation in K18-hACE2 transgenic mice.
    Antiviral Res. 2026 Sep 15:106532. doi: 10.1016/j.antiviral.2026.106532.
    PubMed         Abstract available


    BMJ

  5. WISE J
    Covid-19 inquiry: Additional psychological support for doctors would be rolled out in future pandemic, government says.
    BMJ. 2026;394:e100866.
    PubMed        

  6. WILLMAN D
    US officials knew covid vaccine safety system was flawed-but turned aside the FDA doctor who alerted them.
    BMJ. 2026;394:e100806.
    PubMed        


    Emerg Infect Dis

  7. DUTCHER HA, Antkiewicz DS, Roguet AJ, Shafer MM, et al
    Implementation and Early Outcomes of Laboratory Proficiency Testing Program for the National Wastewater Surveillance System, United States, 2024.
    Emerg Infect Dis. 2026;32:19-25.
    PubMed         Abstract available

  8. BI K, Sandoval M, Nguyen T, Perez I, et al
    Temporal Alignment of Wastewater Signals with Clinical Indicators of Respiratory Illness Postpandemic, Texas, USA.
    Emerg Infect Dis. 2026;32:43-52.
    PubMed         Abstract available

  9. MARK-CAREW M, Bias M, Reckling S, Madhobi K, et al
    Progress and Expansion of the National Wastewater Surveillance System, United States, 2020-2024.
    Emerg Infect Dis. 2026;32:3-13.
    PubMed         Abstract available

  10. LEFFERTS B, Leary A, Bruden D, Blake I, et al
    Wastewater Respiratory Virus Surveillance in Remote Community, Alaska, USA, 2022-2024.
    Emerg Infect Dis. 2026;32:71-79.
    PubMed         Abstract available

  11. MOORE JT, Rose-McCully K, Valencia D, Turner H, et al
    Exploration of Public Perceptions of Wastewater Surveillance, United States, June 2024.
    Emerg Infect Dis. 2026;32:115-118.
    PubMed         Abstract available


    Eur J Radiol

  12. SCHMIDT K, Steinberger M, Woellert S, Klein M, et al
    CT radiation exposure of emergency department patients before, during and after the COVID-19 pandemic.
    Eur J Radiol. 2026;205:113211.
    PubMed         Abstract available


    Int J Infect Dis

  13. HERRERO RL, Jimenez PM, Del Olmo DO, Prieto-Utrera RD, et al
    Epidemiological trends in sepsis in Spain: incidence, in-hospital mortality, and healthcare burden (2017-2022).
    Int J Infect Dis. 2026 Sep 16:109121. doi: 10.1016/j.ijid.2026.109121.
    PubMed         Abstract available

  14. XU M, Huang Y, Ma H, Wu Z, et al
    A Multi-model Counterfactual Analysis of Human Brucellosis in China: Spatiotemporal Epidemiology and Heterogeneous Pandemic-associated Deviations in 2020.
    Int J Infect Dis. 2026 Sep 15:109119. doi: 10.1016/j.ijid.2026.109119.
    PubMed         Abstract available


    J Infect

  15. ORTEGA-FRANCISCO S, Prudente de Aquino MT, Chiuppesi F, Gutierrez-Franco MA Jr, et al
    Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicity.
    J Infect. 2026;93:106855.
    PubMed         Abstract available

  16. HARRIS R, Thirard R, Iftikhar H, Middleditch A, et al
    Corrigendum to "Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: A randomised controlled trial" [J Infect 93 (2026) 106784].
    J Infect. 2026;93:106853.
    PubMed        

  17. BERES SB, Pagnossin D, Olsen RJ, Long SW, et al
    Clinical and population genomic epidemiology of invasive group A streptococcus in Scotland, 2014-2024.
    J Infect. 2026 Sep 18:106860. doi: 10.1016/j.jinf.2026.106860.
    PubMed         Abstract available


    J Med Virol

  18. YANG T, Zhang R, Qin S, Zheng Y, et al
    Cross-Neutralization Responses and Persistent Symptoms After SARS-CoV-2 Breakthrough Infections.
    J Med Virol. 2026;98:e71153.
    PubMed         Abstract available

  19. TURANLI EE, Yildirim Arslan S, Dinc F
    Clinical Outcomes in Pediatric COVID-19 Across Two Time Periods: The Role of Coinfection, Age, and Inflammatory Markers.
    J Med Virol. 2026;98:e71156.
    PubMed         Abstract available


    J Virol

  20. BUGA CC, Valerio M, Alenquer M, Pires de Miranda M, et al
    Insights into the mechanism of action of the bipartite fusion module of SARS-CoV-2 spike protein.
    J Virol. 2026 Sep 15:e0068826. doi: 10.1128/jvi.00688.
    PubMed         Abstract available


    Nature

  21. VARILLY P, Schifferli M, Yang K, Cronan P, et al
    Scalable near-real-time Bayesian phylogenetics for outbreaks with Delphy.
    Nature. 2026 Sep 16. doi: 10.1038/s41586-026-11012.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, September 19 '26)

 


    Arch Virol

  1. SEO H, Rauf A, Seo SH
    Enhanced induction of inflammatory cytokines in human lung cells infected with highly pathogenic recent H5N1/2024 avian influenza virus.
    Arch Virol. 2026;171:278.
    PubMed         Abstract available


    BMC Pediatr

  2. MAITITUERSUN Y, Su R, Yang G, Taerken AY, et al
    A longitudinal study on differential impacts of the COVID-19 pandemic and normalized prevention and control on overweight and obese adolescents in China.
    BMC Pediatr. 2026;26:882.
    PubMed         Abstract available

  3. O'SHEA TM, McGrath M, Douglas J, Blackwell CK, et al
    Child health-related behaviors, social connectedness, and impact of the COVID-19 pandemic on children born preterm in the ECHO Cohort.
    BMC Pediatr. 2026 Jul 20. doi: 10.1186/s12887-026-07337.
    PubMed         Abstract available


    Cell

  4. WU Q, Seydlitz LM, Iakimov V, Hsu DJ, et al
    Dietary arginine drives codon-dependent MHC class I translation and improves immunity in colon tumorigenesis and respiratory viral infection.
    Cell. 2026;189:6012-6023.
    PubMed         Abstract available


    Eur J Epidemiol

  5. KOSTER EAS, Sluiskes MH, Putter H, Rosendaal FR, et al
    Dynamics of infection, vaccination and excess mortality during the COVID-19 pandemic among older individuals-a nationwide analysis.
    Eur J Epidemiol. 2026;41:869-880.
    PubMed         Abstract available

  6. LEHNER CT, Anastasova I, Schauberger G, Eberl M, et al
    Increasing incidence of type 1 diabetes in children and adolescents from 2012 to 2021 in Germany: trends before and during the COVID-19 pandemic.
    Eur J Epidemiol. 2026;41:881-892.
    PubMed         Abstract available


    J Gen Virol

  7. ROSS RA, Walsh SK, Montgomery H, Chen H, et al
    Bovine mammary tissues are susceptible to infection by viruses bearing panzootic H5N1 influenza A virus glycoproteins.
    J Gen Virol. 2026;107:002338.
    PubMed         Abstract available


    J Infect

  8. HARRIS R, Thirard R, Iftikhar H, Middleditch A, et al
    Corrigendum to "Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: A randomised controlled trial" [J Infect 93 (2026) 106784].
    J Infect. 2026;93:106853.
    PubMed        


    PLoS Biol

  9. VALENCA-PEREIRA F, Johnson B, DeGregori J, Rincon M, et al
    Does acute inflammation triggered by infection promote cancer progression?
    PLoS Biol. 2026;24:e3003962.
    PubMed         Abstract available


    PLoS Comput Biol

  10. D'AVANZO M, Myint AP, Cacciapaglia G, Hohenegger S, et al
    From sequences to strategies: Early detection of new SARS-CoV-2 variants via genetic distance to reduce hospitalizations.
    PLoS Comput Biol. 2026;22:e1014707.
    PubMed         Abstract available


    PLoS One

  11. YANG SL, Liu MT, Huang HH, Lin SW, et al
    Epidemiology of human RSV in Taiwan, 2018-2024.
    PLoS One. 2026;21:e0357769.
    PubMed         Abstract available

  12. WOLSKO C, Marino E
    Incorporating public values into public health communications: Effects of value affirmations on intentions to vaccinate and trust in the U.S.
    PLoS One. 2026;21:e0356783.
    PubMed         Abstract available

  13. FUENTES K, Jacobson D, Birze A, Cadel L, et al
    Building capacity in health systems with and for caregivers: A photovoice protocol.
    PLoS One. 2026;21:e0358550.
    PubMed         Abstract available

  14. LI Q, Tang Y, Shi Y, Wu Y, et al
    Census-based adolescent depression risk assessment: A novel method and reflections.
    PLoS One. 2026;21:e0357661.
    PubMed         Abstract available

  15. VENKATESAN S, White L, Koo HN, Dickerson J, et al
    Estimating cumulative incidence from partially missing time series of respiratory viral infections.
    PLoS One. 2026;21:e0353681.
    PubMed         Abstract available

  16. AKTAS N, Ersoy A, Oruc A, Ortac H, et al
    Attitudes, perceptions, behaviours, and concerns of patients listed for kidney transplantation during the COVID-19 pandemic.
    PLoS One. 2026;21:e0358328.
    PubMed         Abstract available

  17. AL-MAGABLEH M, Muhaisen AHM, Ateir RM, Abu Eraq SA, et al
    Herbal or conventional medicine? A cross-sectional study of Jordanian university students' preferences for cold and flu treatment.
    PLoS One. 2026;21:e0358179.
    PubMed         Abstract available

  18. SUERDEM A, Zdravkov S, Ivanov MJ
    Beyond deficit and coexistence: Modeling the knowledge-conspiracy-mistrust configuration in public understanding of science.
    PLoS One. 2026;21:e0341946.
    PubMed         Abstract available

  19. GWANZURA TNR, Trepka MJ, Li T, Juhasz L, et al
    COVID-19 mortality risk among people with HIV in Florida before and after the introduction of COVID-19 vaccines: A population-based study.
    PLoS One. 2026;21:e0358543.
    PubMed         Abstract available

  20. DE VERAS BMG, Michelin L, Croda J, Berra TZ, et al
    Burden of respiratory syncytial virus (RSV) hospitalizations among adults aged 60 years or more in Brazil: A retrospective surveillance database analysis (2013-2024).
    PLoS One. 2026;21:e0357303.
    PubMed         Abstract available


    Vaccine

  21. HOEN L, Lartey S, Pathirana RD, Cox RJ, et al
    Elucidating the role of pre-existing immunity in mucosal lymphoid architectural dynamics following live attenuated influenza vaccination.
    Vaccine. 2026;92:129139.
    PubMed         Abstract available

  22. GUO J, Dai C, Huang Y, Dai J, et al
    Preclinical toxicity and immunogenicity of a quadrivalent recombinant influenza hemagglutinin vaccine (SCVC101) in rhesus monkeys.
    Vaccine. 2026;92:129137.
    PubMed         Abstract available

  23. LAOHARATTANAHIRUN N, Kiertiburanakul S, Boonnak K, Bruminhent J, et al
    Immunogenicity and safety of high-dose versus standard-dose quadrivalent inactivated influenza vaccine in patients living with HIV: a randomized controlled trial.
    Vaccine. 2026;92:129166.
    PubMed         Abstract available

  24. OSTROWSKY JT, Gellin BG, Cavaleri M, Bresee JS, et al
    Innovation, development, and licensure of improved influenza vaccines: the way forward.
    Vaccine. 2026;92:129135.
    PubMed         Abstract available

  25. ZHOU B, Wang J, Knote C
    Seasonal influenza vaccination coverage and population health burden in Europe during the 2019/2020 and 2021/2022 influenza seasons: an ecological panel analysis using principal-component-adjusted multivariable regression.
    Vaccine. 2026;92:129163.
    PubMed         Abstract available

#Australia, #H5 avian #influenza events in #wildlife (DAFF, as of September 19 '26)

 


{Extract}

(...)

Event data

    ° 583 Positive events

    ° 46,904 Hotline reports


    As of 4pm AEST, 18 September 2026, Australia has 583 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 303 in South Australia (SA)

        § 40 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 184 in Victoria (VIC)

        § 43 in Tasmania (TAS)

        § 1 in Other Territories*

{*} Jervis Bay Territory (Commonwealth jurisdiction)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

History of Mass Transportation: The Class 2609 Electric Locomotive at Faro station, Portugal

 


{Click on Image to Enlarge}

___

By Gunnar1m - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=3933943


Source: 


Link: https://en.wikipedia.org/wiki/CP_Class_2600#/media/File:Portuguese_Railways_Intercity_train_at_Faro_Train_Station.jpg

____

Friday, September 18, 2026

First detection of High pathogenicity Avian #Influenza #H5N1 Clade 2.3.4.4b Genotype EA-2024-DI.2.1 in #Egypt associated with migratory wild birds

 


Abstract

High pathogenicity avian influenza (HPAI) H5 clade 2.3.4.4b is the main driver of the ongoing unprecedented global panzootic. The recently emerged HPAI H5N1 clade 2.3.4.4b genotype EA-2024-DI.2.1 has become predominant in Europe, with migratory wild birds, particularly waterfowl, playing a major role in its dissemination. Egypt lies along major Afro-Eurasian migratory flyways, which have historically played an important role in the introduction of emerging H5Nx viruses into the country. In this study, targeted surveillance was conducted on 416 wild birds offered for sale in in live bird markets (LBMs) and roadside trading points in northern Egypt, mainly in Damietta and Port Said. Of these, 118 birds showing mild clinical signs were examined post-mortem and lung and tracheal tissues were collected, while oropharyngeal and cloacal swabs were collected from apparently healthy birds. Avian influenza virus was detected by RT-qPCR in 22 wild birds, all from tissue samples, whereas all swabs from apparently healthy birds were negative. Waterfowl accounted for 16 of the 22 positive birds (72.7%), with Eurasian teal showing the lowest Ct values (21-25). Phylogenetic and whole-genome analyses showed that the sequenced wild-bird viruses clustered within the recently emerged EA-2024-DI.2.1 sub-lineage and were closely related to contemporary European viruses. Compared with the EA-2021-AB genotype currently circulating in Egyptian poultry, the EA-2024-DI.2.1 viruses showed several HA amino acid differences, including A83D, L104M and T195A. These findings provide evidence for the introduction of EA-2024-DI.2.1 into Egypt through migratory wild birds and highlight the importance of continued genomic surveillance at the wild bird domestic poultry interface and antigenic evaluation against vaccines currently used in Egypt.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

the British Council International Science Partnerships Fund (ISPF), UK, grant number 1203757062

the Science, Technology & Innovation Funding Authority (STDF), Egypt., project ID 50185

Source: 


Link: https://doi.org/10.64898/2026.09.12.750890

____

A Decade of Chronic #Hepatitis E #Treatment: #Ribavirin Effectiveness, Safety, and the Association of Torque Teno Virus Load With Treatment Outcomes

 


Highlights

    • Ribavirin achieved 81% SVR in immunocompromised patients with chronic HEV.

    • Adverse events occurred in 56% and led to discontinuation in 17%.

    • Ribavirin dose reduction was associated with failure to achieve SVR.

    • Higher baseline HEV RNA levels were associated with non-SVR.

    • Baseline TTV load showed a nonsignificant trend toward higher levels in non-SVR patients.


Abstract

Background

Hepatitis E virus (HEV) affects immunocompromised individuals. Unlike immunocompetent hosts, who rarely develop chronic infection, up to two-thirds of immunocompromised patients progress to chronicity. Ribavirin is the recommended antiviral therapy, yet predictors of sustained virological response (SVR) remain unclear. Torque Teno Virus (TTV), a marker of immunosuppression, has been proposed as a potential predictor of viral clearance.

Objectives

We evaluated ribavirin treatment outcomes and adverse effects in immunocompromised patients with HEV infection, and assessed whether TTV load predicts SVR.

Study Design

A retrospective cohort study was conducted at the University Medical Center Groningen including solid organ transplant recipients (SOTR) and haematology patients treated with ribavirin for HEV infection between 2010 and 2022. Clinical data and stored serum samples were analysed to determine infection duration and TTV load at treatment initiation and after three months. TTV loads in treated patients were compared with TTV loads of transplant recipients who spontaneously cleared HEV.

Results

Fifty-two patients received ribavirin; 27 had confirmed chronic infection. SVR was achieved in 81% of chronic cases. Adverse events occurred in 56%, leading to dose reduction in 25% and discontinuation in 17%. Non-SVR was associated with ribavirin dose reduction, lower mean daily dose, higher baseline HEV RNA, and lower ALT. Baseline TTV load showed a nonsignificant trend toward higher levels in non-SVR patients. TTV loads did not differ between treated patients and spontaneous clearers.

Conclusions

Ribavirin is effective for chronic HEV, but treatment-limiting toxicity is common. Adequate dosing appears critical for achieving SVR. TTV load did not reliably predict treatment outcome, underscoring the need for further research into immunological and virological predictors of response.

Source: 


Link: https://doi.org/10.1016/j.jcv.2026.106003

_____

Detection of Highly Pathogenic Avian #Influenza #H5N1 Virus in #Cat and #Rats during #Outbreak in Backyard #Poultry, #USA, 2025

 


Abstract

In 2025, highly pathogenic avian influenza A(H5N1) virus was detected in a poultry flock in Illinois, USA. Quantitative reverse transcription PCR, sequencing, and histopathology on cat and rat samples from the farm showed multiple positive tissues and high sequence identity to an avian isolate. Small mammals might contribute to H5N1 transmission.

Source: 


Link: https://doi.org/10.3201/eid3210.260418

____

#USA, #Wastewater Data for Avian #Influenza #H5 (US CDC, September 18 '26)

 


{Excerpt}

(...)

A(H5) detections in the past week

Time Period: September 06, 2026 - September 12, 2026

    ° A(H5) Detection:  2 site(s) (0.5%)

    ° No Detection415 site(s) (99.5%)

    ° No samples131 site(s)


{Click on Image to Enlarge}

___



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

Seasonal #surveillance in #humans in 2026 for #WNV - Weekly Report (ECDC, September 18 '26): 1,482 cases so far, of which 652 in #Italy

 


{Summary}

Week 38, 2026Published on 18 September 2026, based on data submitted up until and including 17 September 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 17 September, 180 areas affected by West Nile virus (WNV) have been identified in 16 countries across Europe.

    ° These areas are located in: 

        § Italy (65), 

        § Greece (22), 

        § Romania (22), 

        § France (19), 

        § the Netherlands (13), 

        § Serbia (8), 

        § Croatia (5), 

        § Spain (5), 

        § Belgium (4), 

        § North Macedonia (4), 

        § Germany (3), 

        § Hungary (3), 

        § Austria (2), 

        § Kosovo (2), 

        § Albania (1) and 

        § Cyprus (1).

    ° This week, 19 areas are reported as affected for the first time this season. 

    ° The 16 countries have reported 1 482 locally acquired human cases of WNV infection: 

        § Italy (652 cases), 

        § Greece (355 cases, of which 8 had an unknown place of infection), 

        § Spain (114 cases), 

        § Romania (91 cases), 

        § France (81 cases), 

        § North Macedonia (66 cases), 

        § Serbia (43 cases), 

        § the Netherlands (29 cases), 

        § Croatia (13 cases), 

        § Cyprus (11 cases), 

        § Belgium (9 cases), 

        § Austria (6 cases, of which 1 had an unknown place of infection), 

        § Germany (4 cases), 

        § Hungary (4 cases), 

        § Albania (2 cases) and 

        § Kosovo (2 cases)

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

My New Space

Most Popular Posts